Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors.
Puri
R K
RK
Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA.
D036002:ADP Ribose Transferases; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D001427:Bacterial Toxins; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017321:Clinical Trials, Phase I as Topic; D005098:Exotoxins / Q000627:therapeutic use*; D005909:Glioblastoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006168:Guinea Pigs; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015552:Injections, Intralesional; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007278:Injections, Spinal; D015847:Interleukin-4 / Q000502:physiology*; D008252:Macaca fascicularis; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000737:chemistry / Q000187:drug effects*; D009447:Neuroblastoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D017434:Protein Structure, Tertiary; D051381:Rats; D019948:Receptors, Interleukin-4 / Q000737:chemistry / Q000187:drug effects*; D016896:Treatment Outcome; D014410:Tumor Stem Cell Assay; D037521:Virulence Factors; D023041:Xenograft Model Antitumor Assays; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000970:Antineoplastic Agents; D001427:Bacterial Toxins; D005098:Exotoxins; D000922:Immunotoxins; D015847:Interleukin-4; D009363:Neoplasm Proteins; D019948:Receptors, Interleukin-4; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C120228:interleukin 4 (38-37)-PE38KDEL